Diabetic retinopathy is the leading cause of blindness in 20-64 year olds. Recent studies report that patients with diabetes after 15 years will develop Diabetic Retinopathy or have some degree of retinal damage.

Treatment options focus mainly on the last stages of the disease. Although it is a health challenge, science is lagging in treatment options, especially in the early stages of the disease where excess blood glucose attacks the vessel walls and leads to gradual degeneration of the vessels by increasing oxidative stress and inflammation. In addition to diabetic retinopathy, patients with diabetes have an increased risk of developing vein occlusion. Although in this particular case atherosclerosis is the most common cause. In vein occlusion, the retinal vein is blocked, preventing normal blood flow and leading to inflammation.

Retinoaspis is a specialized preparation for the prevention and treatment of diabetic retinopathy and retinal vein occlusion.

It manages diabetic retinopathy by supporting the metabolism, structure and function of retinal cells.
It has a strong anti-inflammatory effect by promoting the production of anti-inflammatory cytokines. A key anti-inflammatory component is docosahexaenoic acid (DHA) which is a necessary component for the functioning of the body and cannot be synthesized by itself.
It has an antioxidant effect by providing the necessary antioxidant mechanism to the retina. Astaxanthin, contained in the product, is literally hundreds of times stronger than other antioxidant molecules. Astaxanthin comes from the algae of the genus Haematococcus pluvialis and is a natural carotenoid.
It meets the body's vitamin needs, regulates homocysteine levels and provides an additional anti-inflammatory effect with vitamin B12.
The composition with clinically proven ingredients:

Delays the onset of diabetic retinopathy in patients with type I and type II diabetes.
It slows the progression of diabetic retinopathy and retinal vein occlusion.
It helps suppress retinal inflammation in patients who are at an advanced stage and have developed edema by acting synergistically with medication to reduce swelling.
Send feedback
Side panels
History
Saved
Contribute